

Reference:	FOI.3402.20
Subject:	New Ophthalmology patients
Date of Request:	19 June 2020

Requested:

Freedom of Information request regarding Ophthalmology new patients.
I would be grateful if you could answer the questions below.

1. Within your Trust, how many patients, in the most recent 12-month period for which data are available, have received anti-VEGF treatment **for the first time** (i.e., excluding patients who previously had any anti-VEGF therapy)?
2. Of these first-time patients, please provide a breakdown by the treatments listed below:
Aflibercept
Brolucizumab
Dexamethasone
Ranibizumab
All other anti-VEGF treatments
3. Of these first-time patients, how many were treated for Wet Age-Related Macular Degeneration (wAMD) by each treatment?
Aflibercept
Brolucizumab
Dexamethasone
Ranibizumab
All Other anti-VEGF treatments

Response:

1. Hywel Dda University Health Board (UHB) confirms two hundred and seven (207) patients received anti-Vascular Endothelial Growth Factor (VEGF) treatment for the first time for the period 1 June 2019 and 31 May 2020.
2. The UHB provides, within the table below, the number of first time patients that received the treatments listed.

Treatment	Number of patients
Aflibercept	63
Brolucizumab	0
Dexamethasone	0
Ranibizumab	143
All other anti-VEGF treatments	0

3. The UHB provides, within the table below, the number of first time patients treated for Age-Related Macular Degeneration (wAMD) with the treatments listed.

Treatment	Number of patients
Aflibercept	42
Brolucizumab	0
Dexamethasone	0
Ranibizumab	120
All other anti-VEGF treatments	0